AFIB · As filed with the SEC

Acutus Medical balance sheet, by quarter

The statement as Acutus Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	14,019	12,595	13,327	18,459
Marketable securities, short-term	0	0	0	1,495
Restricted cash, short-term	0	0	0	0
Accounts receivable	7,878	9,970	9,235	7,750
Inventory	1,790	4,191	5,213	5,888
Prepaid expenses and other current assets	641	403	507	572
Current assets of discontinued operations (Note 3)	1,250	0	175	240
Total current assets	25,578	27,159	28,457	34,404
Noncurrent assets
Property and equipment, net	517	736	808	844
Right-of-use assets, net	2,459	2,647	2,831	3,011
Other assets	94	94	94	94
Non-current assets of discontinued operations (Note 3)	0	1,531	3,284	3,315
Total assets	28,648	32,167	35,474	41,668
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Accounts payable	1,276	1,711	1,683	3,165
Accrued liabilities	3,006	1,702	1,609	2,063
Operating lease liabilities, short-term	957	897	886	835
Long-term debt, current portion	7,005	7,084	7,055	1,819
Warrant liability	194	302	128	692
Current liabilities of discontinued operations (Note 3)	0	2,969	1,017	1,300
Total current liabilities	12,438	14,665	12,378	9,874
Operating lease liabilities, long-term	2,238	2,532	2,771	3,009
Long-term debt	25,564	25,269	25,130	32,805
Total liabilities	40,240	42,466	40,279	45,688
Stockholders' (deficit) equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	0	0	0	0
Common stock, $0.001 par value; 260,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 29,912,305 and 29,313,667 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	30	30	30	30
Additional paid-in capital	598,670	598,670	598,542	598,413
Accumulated deficit	(609,524)	(608,118)	(602,511)	(601,597)
Accumulated other comprehensive loss	(768)	(881)	(866)	(866)
Total stockholders' deficit	(11,592)	(10,299)	(4,805)	(4,020)
Total liabilities and stockholders' deficit	28,648	32,167	35,474	41,668

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.